Mobilizing the
Human Immune System
to Combat Disease
HiFiBiO Therapeutics is an emerging multinational company that will soon transform patient care.
Home
Mobilizing the
Latest News
May 9, 2022
Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management
CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer. “We are very excited to bring on board an … Continued
Apr 27, 2022
HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, MA – April 27th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Alexander I Spira, MD, PhD, FACP, Co-Director of the Virginia Cancer Specialists (VCS) Research Institute and Director of the Thoracic and Phase I Program, will present a Trials in Progress Poster for HFB200301 on Sunday, … Continued
May 9, 2022
Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management
CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer. “We are very excited to bring on board an … Continued
Unprecedented Discovery and Development Engine
Drug Discovery and Development Expertise
Back
Drug Discovery and Development Expertise
• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients
Transformational Single-Cell Platform
Back
Transformational Single-Cell Platform
• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success
Dynamic and Sustainable Pipeline
Back
Dynamic and Sustainable Pipeline
• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models
Unique Immune Profiling Translational Focus
Back
Unique Immune Profiling Translational Focus
• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action
Open-Innovation Strategy
Back
Open-Innovation Strategy
• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy
• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients
• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success
• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models
• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action
• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy